Pluri Inc.: financial analysis
Ratios worked out from 10 fiscal years of Pluri Inc.'s statements, compared with 665 companies in Biotechnology.
Pluri Inc. scorecard#
Passes 3 of the 17 checks that could be worked out: strongest in growth (3 of 5), weakest in valuation (0 of 5). Fiscal year 2026; market cap of Oct 29, 2026.
Valuation0 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- ✗Price to sales below its peers' median10.4×Price to sales 10.4× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-133.2%Free cash flow is -133.2% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 5
- ✗Revenue grew in the newest year-23.9%Revenue down 23.9% in fiscal 2026.
- ✓Revenue up more than 5% a year over three years52.1%52.1% a year over the three years to fiscal 2026.
- ✓Faster growth over three years than its peers' median52.1%52.1% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-2.44 vs -3.56Diluted EPS -2.44 in fiscal 2026 against -3.56 the year before (report's currency).
- ✓Net income higher than five years earlier-$24 M-$24 M in fiscal 2026 against -$50 M in 2021.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$24 MNet income -$24 M in fiscal 2026.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2026.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health0 of 4
- ✗Short-term assets cover short-term liabilities0.3×Current ratio 0.27 at the end of fiscal 2026.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- ✗Operating income covers interest five times-26.8×Operating income -26.8 times interest in fiscal 2026.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2026.
- ✗Altman Z-score outside the distress zone-30.48Z-score -30.48 (distress zone) for fiscal 2026.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year53.8%Diluted shares up 53.8% in fiscal 2026.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2026 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Worth a look
- Revenue fell 23.9% against the year before.
- Net loss of $24 million, the 17th loss-making year in a row.
- Free cash flow was negative: -$20 million.
- The share count rose 53.8% in the year.
- Shareholders' equity is negative: -$23 million.
- Operating income covers the interest bill only -26.8 times.
- Liabilities due within a year exceed current assets (current ratio 0.27).
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profitno
- Operations brought in cashno
- Return on assets roseno
- Cash from operations exceeds profityes
- Long-term debt fell against assetsnot on file
- Current ratio roseno
- No new shares issuedno
- Gross margin roseno
- Asset turnover roseyes
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | -0.96 | × 1.2 | -1.16 |
| Retained earnings to assets | -18.77 | × 1.4 | -26.27 |
| Operating income to assets | -1.00 | × 3.3 | -3.31 |
| Market value to liabilities | 0.36 | × 0.6 | 0.22 |
| Revenue to assets | 0.04 | × 1 | 0.04 |
Profitability#
| Fiscal year | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 44.1% | 48.5% | — | — | — | 74.8% | 19% | |
| Return on equity | — | — | -310.4% | -130.5% | -94.6% | -61.0% | — | |
| Return on assets | -75.0% | -57.7% | -46.3% | -47.7% | -51.0% | -44.4% | 29% |
Growth#
| Fiscal year | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | -23.9% | 306.1% | — | — | — | 15.8% | 18% | |
| Revenue growth, 3 years a year | 52.1% | 79.9% | — | — | — | 12.9% | 79% |
Financial strength#
| Fiscal year | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Interest cover | -26.82× | -25.49× | -25.47× | -32.44× | -46.73× | -22.77× | 45% | |
| Current ratio | 0.27× | 0.68× | 6.99× | 7.37× | 8.46× | 4.39× | 5% | |
| Equity share of assets | -92.6% | -17.7% | 0.3% | 26.3% | 44.1% | 64.7% | 8% |
Cash#
| Fiscal year | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $-20 M | $-20 M | $-18 M | $-23 M | $-37 M | $-40 M | 64% | |
| Capital spending share of revenue | 61.8% | 120.9% | — | — | — | 1.7% | — |
Efficiency#
| Fiscal year | Trend | 2026 | 2025 | 2024 | 2023 | 2022 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.03× | 0.03× | — | — | — | 0.26× | 8% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).
Source: Pluri Inc.'s statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 665 companies in Biotechnology that Pluri Inc. is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Pluri Inc.